{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:21:42Z","timestamp":1783164102164,"version":"3.54.6"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11423-z","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:01:47Z","timestamp":1766149307000},"page":"4719-4757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Contemporary trends on the kinase inhibitors with special reference to quinoxaline derivatives"],"prefix":"10.1007","volume":"30","author":[{"given":"Kirti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikant","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"11423_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971\u2013979","journal-title":"J Pharmacol Exp Ther"},{"key":"11423_CR2","doi-asserted-by":"publisher","first-page":"17600","DOI":"10.3390\/ijms242417600","volume":"24","author":"S Silnitsky","year":"2023","unstructured":"Silnitsky S, Rubin SJS, Zerihun M, Qvit N (2023) An update on protein kinases as therapeutic Targets\u2014part I: protein kinase C activation and its role in cancer and cardiovascular diseases. Int J Mol Sci 24:17600","journal-title":"Int J Mol Sci"},{"key":"11423_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.942500","volume":"10","author":"K Riegel","year":"2022","unstructured":"Riegel K, Vijayarangakannan P, Kechagioglou P, Bogucka K, Rajalingam K (2022) Recent advances in targeting protein kinases and pseudokinases in cancer biology, front. Cell Dev Biol 10:1\u201316. https:\/\/doi.org\/10.3389\/fcell.2022.942500","journal-title":"Cell Dev Biol"},{"key":"11423_CR4","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/jm500065f","volume":"57","author":"IG Salado","year":"2014","unstructured":"Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A (2014) Perez, D. I. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem 57:6, 2755\u20132772","journal-title":"J Med Chem"},{"key":"11423_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen P (2002) Protein kinases-the major drug targets of the twenty-first century. Nat Rev Drug Discov 1:309\u2013315","journal-title":"Nat Rev Drug Discov"},{"key":"11423_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0163-7258(98)00056-4","volume":"82","author":"JD Graves","year":"1999","unstructured":"Graves JD, Krebs EG (1999) Protein phosphorylation, and signal transduction. Pharmacol Ther 82:111\u2013121","journal-title":"Pharmacol Ther"},{"key":"11423_CR7","unstructured":"Spherical Insight, Global Kinase Inhibitors Market, 2023, https:\/\/www.sphericalinsights.com\/press-release\/kinase-inhibitors-market#:~:text=Kinase%20Inhibitors%20Market%20Size%20To%20Grow%20USD%2095.3%20Bn%20By%202030, Accessed 1 July 2025 https:\/\/www.sphericalinsights.com\/reports\/kinase-inhibitors-market}"},{"key":"11423_CR8","doi-asserted-by":"crossref","unstructured":"Vaughn JE, Zhao Q, Marcucci M, Sharma N, Mims A, Waller A, Stein J (2024) Understanding valuation of tyrosine kinase inhibitors among patients with chronic myeloid leukemia using a novel hypothetical purchasing task. Blood 144:5049","DOI":"10.1182\/blood-2024-203641"},{"key":"11423_CR9","doi-asserted-by":"publisher","first-page":"e009586","DOI":"10.1136\/bmjopen-2015-009586","volume":"6","author":"D Andrew Hill, Gotham","year":"2016","unstructured":"Andrew Hill, Gotham D, Fortunak J, Meldrum J, Erbacher I, Martin M, Shoman H, Levi J, Powderly WG, Bower M (2016) Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open 6:e009586. https:\/\/doi.org\/10.1136\/bmjopen-2015-009586","journal-title":"BMJ Open"},{"key":"11423_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","volume":"65","author":"CC Ayala-Aguilera","year":"2022","unstructured":"Ayala-Aguilera CC, Valero T, Lorente-Mac\u00edas \u00c1, Baillache DJ, Croke S, Unciti-Broceta A (2022) Small molecule kinase inhibitor drugs (1995\u20132021): medical Indication, pharmacology, and synthesis. J Med Chem 65:(2):1047\u20131131","journal-title":"J Med Chem"},{"key":"11423_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0092-8674(00)81092-2","volume":"85","author":"LN Johnson","year":"1996","unstructured":"Johnson LN, Noble ME, Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85:149\u2013158","journal-title":"Cell"},{"key":"11423_CR12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1126\/science.1095920","volume":"303","author":"ME Noble","year":"2004","unstructured":"Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800\u20131805","journal-title":"Science"},{"issue":"6","key":"11423_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","volume":"20","author":"DK Treiber","year":"2013","unstructured":"Treiber DK, Shah NP (2013) Ins and outs of kinase DFG motifs. Chem Biol 20(6):745\u2013746","journal-title":"Chem Biol"},{"key":"11423_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/jm501603h","volume":"58","author":"RSK Vijayan","year":"2015","unstructured":"Vijayan RSK, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL Jr., Levy RM (2015) Conformational analysis of the DFG-Out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem 58:466\u2013479","journal-title":"J Med Chem"},{"key":"11423_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"RJ Roskoski","year":"2016","unstructured":"Roskoski RJ (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26\u201348","journal-title":"Pharmacol Res"},{"key":"11423_CR16","doi-asserted-by":"publisher","first-page":"13130","DOI":"10.1039\/D4SC01088D","volume":"15","author":"B Biswas","year":"2024","unstructured":"Biswas B, Huang Y-H, Craik DJ, Wang CK (2024) The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance. Chem Sci 15:13130","journal-title":"Chem Sci"},{"key":"11423_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046\u20131051","journal-title":"Nat Biotechnol"},{"key":"11423_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nchembio.1938","volume":"11","author":"S M\u00fcller","year":"2015","unstructured":"M\u00fcller S, Chaikuad A, Gray NS, Knapp S (2015) The Ins and outs of selective kinase inhibitor development. Nat Chem Biol 11:818\u2013821","journal-title":"Nat Chem Biol"},{"key":"11423_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/molecules23040908","volume":"23","author":"F Carles","year":"2018","unstructured":"Carles F, Bourg S, Meyer C, Bonnet P (2018) PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials. Molecules 23:908","journal-title":"Molecules"},{"key":"11423_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","volume":"6","author":"CC Ayala-Aguilera","year":"2022","unstructured":"Ayala-Aguilera CC, Valero T, Lorente-Mac\u00edas \u00c1, Baillache DJ, Croke S, Unciti-Broceta A (2022) Small molecule kinase inhibitor drugs (1995\u20132021): medical Indication, pharmacology, and synthesis, A. J Med Chem 6:1047\u20131131","journal-title":"J Med Chem"},{"key":"11423_CR21","unstructured":"University of Dundee, MRC Protein Phosphorylation and Ubiquitylation Unit (2022) https:\/\/www.ppu.mrc.ac.uk\/list-clinically-approved-kinase-inhibitors. Accessed 1 July 2025"},{"key":"11423_CR22","doi-asserted-by":"publisher","unstructured":"Kumar A, Dhameliya TM, Sharma K, Patel KA, Hirani RV, Bhatt AJ (2022) Sustainable approaches towards the synthesis of quinoxalines: an update. J. Mol. Structures. https:\/\/doi.org\/10.1016\/j.molstruc.2022.132732","DOI":"10.1016\/j.molstruc.2022.132732"},{"key":"11423_CR23","doi-asserted-by":"publisher","DOI":"10.1515\/9783110985627-005","volume-title":"Water as benign reaction medium for the synthesis of quinoxalines","author":"B Tanwar","year":"2024","unstructured":"Tanwar B, Kumar A, Saha N, Chakraborti AK (2024) Water as benign reaction medium for the synthesis of quinoxalines. Walter de Gruyters GmbH, Berlin."},{"key":"11423_CR24","doi-asserted-by":"publisher","unstructured":"Sharma K, Sharma A, Sanduja M, Jogpal V, Kumar A, Abdulsalam A (2024) Unravelling the design and mechanism: potential of substituted 2,3-Diaryl-Quinoxalines as DprE1 inhibitors for antitubercular activity. Open Chem 22. https:\/\/doi.org\/10.1515\/chem-2024-0086. De Gruyter","DOI":"10.1515\/chem-2024-0086"},{"key":"11423_CR25","doi-asserted-by":"publisher","unstructured":"Jadhavar PS, Kumar D, Purohit P, Pipaliya BV, Kumar A, Bhagat S, Chakraborti AK (2014) Sustainable approaches towards the synthesis of Quinoxalines, green chemistry: synthesis of bioactive heterocycles. Springer India. https:\/\/doi.org\/10.1007\/978-81-322-1850-0_2","DOI":"10.1007\/978-81-322-1850-0_2"},{"issue":"Issue16","key":"11423_CR26","doi-asserted-by":"publisher","first-page":"e202400194","DOI":"10.1002\/slct.202400194","volume":"9","author":"K Sharma","year":"2024","unstructured":"Sharma K, Sharma A, Sanduja M, Kumar A (2024) Unravelling the design and mechanism: potential of substituted Quinolines as PASTA subunit 4 inhibitors for antimicrobial activity. ChemsistrySelect 9(16):e202400194. https:\/\/doi.org\/10.1002\/slct.202400194","journal-title":"ChemsistrySelect"},{"key":"11423_CR27","volume-title":"Catalyst-free synthesis of monocyclic heterocycles in aqueous medium: a sustainable approach","author":"A Kumar","year":"2024","unstructured":"Kumar A, Saha N, Biswas S, Chakraborti AK (2024) Catalyst-free synthesis of monocyclic heterocycles in aqueous medium: a sustainable approach. Walter de Gruyters GmbH, Berlin."},{"key":"11423_CR28","doi-asserted-by":"publisher","first-page":"e202201059","DOI":"10.1002\/slct.202201059","volume":"7","author":"A Kumar","year":"2022","unstructured":"Kumar A, Dhameliya TM, Sharma K, Patel KA, Hirani RV (2022) Environmentally benign approaches towards the synthesis of Quinolines. ChemsitrySelect 7:e202201059. https:\/\/doi.org\/10.1002\/slct.202201059","journal-title":"ChemsitrySelect"},{"key":"11423_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HP (2018) V. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 17:48","journal-title":"Mol Cancer"},{"key":"11423_CR30","doi-asserted-by":"crossref","unstructured":"Aliya MS, El Newahie YM, Nissan, Nasser SM, Ismail DA, Abou E, Ella SM, Khojah, Khaled AM, Abouzid (2019) Design and synthesis of new quinoxaline derivatives as anticancer agents and apoptotic inducers. Molecules 24:1175","DOI":"10.3390\/molecules24061175"},{"key":"11423_CR31","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.ejmech.2011.03.015","volume":"46","author":"MN Noolvi","year":"2011","unstructured":"Noolvi MN, Patel HM, Bhardwaj V, Chauhan A (2011) Synthesis and in vitro antitumor activity of substituted Quinazoline and Quinoxaline derivatives: search for anticancer agent. Eur J Med Chem 46:2327\u20132346","journal-title":"Eur J Med Chem"},{"key":"11423_CR32","first-page":"1684","volume":"71","author":"X Hu","year":"2019","unstructured":"Hu X, Wan C, Gan Z, Liu R, Chen Y, Wang J, Gan L, Chen Y, Li Y, He B, Yu Y (2019) Tnbg-5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor \u03b3 in vitro and in vivo. J Physiol Pharmacol 71:11, 1684\u20131694","journal-title":"J Physiol Pharmacol"},{"key":"11423_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejmech.2018.11.059","volume":"163","author":"M Ma","year":"2019","unstructured":"Ma M, Fa M, Ta T, Pa V (2019) Antitumoral activity of Quinoxaline derivatives: a systematic review. Eur J Med Chem 163:136\u2013147","journal-title":"Eur J Med Chem"},{"key":"11423_CR34","doi-asserted-by":"publisher","first-page":"24573","DOI":"10.1021\/acsomega.3c02797","volume":"8","author":"D Osmaniye","year":"2023","unstructured":"Osmaniye D, Bozkurt NB, Levent S, Yard\u0131m GB, Sa\u011fl\u0131k BN, Ozkay Y, Kaplanc\u0131kli ZA, Synthesis (2023) Antifungal Activities, molecular Docking and molecular dynamic studies of novel Quinoxaline-Triazole compounds. ACS Omega 8:24573\u201324585","journal-title":"ACS Omega"},{"key":"11423_CR35","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1039\/D1RA07559D","volume":"12","author":"X Tang","year":"2022","unstructured":"Tang X, Zhou Q, Zhan W, Hu D, Zhou R, Sun N, Chen S, Wu W, Xue W (2022) Synthesis of novel antibacterial and antifungal Quinoxaline derivatives. RSC Adv 12:2399\u20132407","journal-title":"RSC Adv"},{"key":"11423_CR36","doi-asserted-by":"publisher","first-page":"36989","DOI":"10.1039\/D1RA06799K","volume":"11","author":"YM Syam","year":"2021","unstructured":"Syam YM, Anwar MM, Abd El-Karim SS, Elseginy SA, Essa BM, Sakr TM (2021) New Quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies. RSC Adv 11:36989\u201337010","journal-title":"RSC Adv"},{"key":"11423_CR37","doi-asserted-by":"crossref","unstructured":"Khatoon H, Malek EA, Faudzi SM, Rukayadi Y (2024) Synthesis of a series of quinoxaline derivatives and their antibacterial effectiveness against pathogenic bacteria. ChemistrySelect 9(7):e202305073","DOI":"10.1002\/slct.202305073"},{"key":"11423_CR38","doi-asserted-by":"publisher","first-page":"116675","DOI":"10.1016\/j.ejmech.2024.116675","volume":"276","author":"H Khatoon","year":"2024","unstructured":"Khatoon H, Faudzi SMM (2024) Exploring Quinoxaline derivatives: an overview of a new approach to combat antimicrobial resistance. Eur J Med Chem 276:116675","journal-title":"Eur J Med Chem"},{"issue":"5","key":"11423_CR39","doi-asserted-by":"publisher","first-page":"2000449","DOI":"10.1002\/ardp.202000449","volume":"354","author":"HS Abulkhair","year":"2021","unstructured":"Abulkhair HS, Elmeligie S, Ghiaty A, El-Morsy A, Bayoumi AH, Ahmed HEA, El-Adl K, Zayed MF, Hassan MH, Akl EN (2021) El-Zoghbi, in vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors. Arch Pharm 354(5):2000449","journal-title":"Arch Pharm"},{"issue":"16","key":"11423_CR40","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.3390\/molecules26164742","volume":"26","author":"M Montana","year":"2021","unstructured":"Montana M, Montero V, Khoumeri O, Vanelle P (2021) Quinoxaline moiety: A potential scaffold against Mycobacterium tuberculosis. Molecules 26(16):4742","journal-title":"Molecules"},{"key":"11423_CR41","doi-asserted-by":"publisher","unstructured":"Rawat M, Padalino G, Yeo T, Brancale A, Fidock DA, Hoffmann KF, Lee MCS BioRxiv [Preprint]. 2024 Apr 24:2024.04.23.590861. [Version 1] https:\/\/doi.org\/10.1101\/2024.04.23.590861","DOI":"10.1101\/2024.04.23.590861"},{"key":"11423_CR42","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1016\/j.bmc.2018.06.033","volume":"26","author":"J Cogo","year":"2018","unstructured":"Cogo J, Cantizani J, Cotillo I, Sangi DP, Corr\u00eaa AG, Ueda- Nakamura T, Filho BPD, Mart\u00edn JJ, Nakamura CV (2018) Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents. Bioorg Med Chem 26:4065\u20134072","journal-title":"Bioorg Med Chem"},{"key":"11423_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ejmech.2008.02.002","volume":"44","author":"A Budakoti","year":"2009","unstructured":"Budakoti A, Bhat AR, Azam A (2009) Synthesis of new 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives and evaluation of their antiamoebic activity. Eur J Med Chem 44:1317\u20131325","journal-title":"Eur J Med Chem"},{"key":"11423_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1021\/acsmedchemlett.8b00150","volume":"9","author":"LN Rusere","year":"2018","unstructured":"Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Yilmaz NK, Schiffer CA, Ali A (2018) Quinoxaline-Based linear HCV NS3\/4A protease inhibitors exhibit potent activity against drug resistant variants. ACS Med Chem Lett 9:7, 691\u2013696","journal-title":"ACS Med Chem Lett"},{"key":"11423_CR45","doi-asserted-by":"publisher","first-page":"25204","DOI":"10.1039\/D2RA04498F","volume":"12","author":"EA Ahmed","year":"2022","unstructured":"Ahmed EA, Mohamed MFA, Omran OA (2022) Novel Quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular Docking and biological evaluation as potential anticancer and anti-inflammatory agents. RSC Adv 12:25204\u201325216","journal-title":"RSC Adv"},{"key":"11423_CR46","doi-asserted-by":"publisher","first-page":"101989","DOI":"10.1016\/j.rechem.2024.101989","volume":"13","author":"AM Waseem","year":"2025","unstructured":"Waseem AM, Elmagzoub RM, Abdelgadir MMM, Bahir AA, EL-Gawaad NSA, Abdel-Samea AS, Rao DP, Kossenas K, Br\u00e4se S, Hashem H (2025) An insight into the therapeutic impact of Quinoxaline derivatives: recent advances in biological activities (2020\u20132024). Results Chem 13:101989","journal-title":"Results Chem"},{"key":"11423_CR47","doi-asserted-by":"publisher","first-page":"115942","DOI":"10.1016\/j.ejmech.2023.115942","volume":"263","author":"V Mehta","year":"2023","unstructured":"Mehta V, Dwivedi AR, Ludhiadch A, Rana V, Goel KK, Uniyal P, Joshi G, Kumar A, Kumar B (2023) A decade of USFDA-approved small molecules as anti-inflammatory agents: recent trends and commentaries on the industrial perspective. Eur J Med Chem 263:115942","journal-title":"Eur J Med Chem"},{"key":"11423_CR48","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2174\/0113895575264375231012115026","volume":"24","author":"TA Farghaly","year":"2024","unstructured":"Farghaly TA, Alqurashi RM, Masaret GS, Gaber H (2024) Recent methods for the synthesis of Quinoxaline derivatives and their biological activities. Min Rev Med Chem 24:920\u2013982","journal-title":"Min Rev Med Chem"},{"key":"11423_CR49","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al (2020) Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today. Accessed 9 Dec 2025"},{"issue":"21","key":"11423_CR50","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.3390\/molecules27217480","volume":"27","author":"H Wang","year":"2022","unstructured":"Wang H, He Y, Jian M, Fu X, Cheng Y, He Y, Fang J, Li L, Zhang D (2022) Breaking the bottleneck in anticancer drug development: efficient utilization of synthetic biology. Molecules 27(21):7480","journal-title":"Molecules"},{"key":"11423_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, Falco VD, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Lastra J (2023) M. P. d. l. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10:1367\u20131401","journal-title":"Genes Dis"},{"key":"11423_CR52","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.tetlet.2007.11.204","volume":"49","author":"J Gris","year":"2008","unstructured":"Gris J, Glisoni R, Fabian L, Fern\u00e1ndez B, Moglioni AG (2008) Synthesis of potential chemotherapic Quinoxalinone derivatives by biocatalysis or microwave-assisted Hinsberg reaction. Tet Lett 49:1053\u20131056","journal-title":"Tet Lett"},{"key":"11423_CR53","first-page":"195","volume":"18","author":"IH Eissa","year":"2018","unstructured":"Eissa IH, El-Naggar AM, El-Sattar NEA, Abd, Youssef ASA (2018) Design and discovery of novel Quinoxaline derivatives as dual DNA intercalators and topoisomerase II Inhibitors, anti-cancer agent. Med Chem 18:195\u2013209","journal-title":"Med Chem"},{"key":"11423_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bmc.2018.11.021","volume":"27","author":"T Kaushala","year":"2019","unstructured":"Kaushala T, Srivastavaa G, Sharmaa A, Negia A (2019) An insight into medicinal chemistry of anticancer quinoxalines. Bioorg Med Chem 27:16\u201335","journal-title":"Bioorg Med Chem"},{"key":"11423_CR55","doi-asserted-by":"crossref","unstructured":"Shibuya M (2011) Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis. Genes & Cancer 12:1097\u20131105. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1947601911423031","DOI":"10.1177\/1947601911423031"},{"key":"11423_CR56","doi-asserted-by":"crossref","unstructured":"Ghorab MM, Alsaid MS, Soliman AM, Ragab FA (2017) VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo [g] quinazoline bearing benzenesulfonamide moiety. J. Enzyme Inhib. Med. Chem 32:893\u2013907","DOI":"10.1080\/14756366.2017.1334650"},{"key":"11423_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"PR Carmeliet","year":"2011","unstructured":"Carmeliet PR, Jain K (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298\u2013307","journal-title":"Nature"},{"key":"11423_CR58","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1039\/D0QO01575J","volume":"8","author":"G Yashwantrao","year":"2021","unstructured":"Yashwantrao G, Saha S (2021) Recent advances in the synthesis and reactivity of Quinoxaline. Org Chem Front 8:2820\u20132862","journal-title":"Org Chem Front"},{"key":"11423_CR59","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.rechem.2024.101389","volume":"7","author":"H Khatoon","year":"2024","unstructured":"Khatoon H, Malek EA, Faudzi SMM, Khan T, Ahmed OS (2024) Synthesis of Quinoxaline derivatives using different solvent systems, their potent antibacterial activities and molecular docking. Result Chem 7:101389","journal-title":"Result Chem"},{"issue":"3","key":"11423_CR60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/bies.10043","volume":"24","author":"JH Harmey","year":"2002","unstructured":"Harmey JH, Bouchier-Hayes D (2002) Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. BioEssays 24(3):280\u2013283","journal-title":"BioEssays"},{"issue":"12","key":"11423_CR61","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis a crucial target for Anti- and Pro-angiogenic therapies. Genes Cancer 2(12):1097\u20131105","journal-title":"Genes Cancer"},{"key":"11423_CR62","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","volume":"45","author":"K Lee","year":"2010","unstructured":"Lee K, Jeong K-W, Lee Y, Song JY, Kim MS, Lee GS, Kim Y (2010) Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 45:5420\u20135427","journal-title":"Eur J Med Chem"},{"issue":"2","key":"11423_CR63","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2013.11.029","volume":"132","author":"RN Eskander","year":"2014","unstructured":"Eskander RN, Tewari KS (2014) Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma\u2014mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 132(2):496\u2013505","journal-title":"Gynecol Oncol"},{"key":"11423_CR64","doi-asserted-by":"crossref","unstructured":"Abdelgalil AA, Alkahtani HM, Fahad I, Al-Jenoobi (2019) Chapter Four \u2013 Sorafenib. Profiles Drug Subst Excip Relat Methodol 44:239\u2013266","DOI":"10.1016\/bs.podrm.2018.11.003"},{"key":"11423_CR65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13065-024-01135-0","volume":"18","author":"HT Abdel-Mohsen","year":"2024","unstructured":"Abdel-Mohsen HT, Ibrahim MA, Nageeb AM, Kerdawy AME (2024) Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC Chem 18:42","journal-title":"BMC Chem"},{"key":"11423_CR66","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835\u2013844","journal-title":"Nat Rev Drug Discov"},{"key":"11423_CR67","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio799","volume":"2","author":"Y Liu","year":"2006","unstructured":"Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358\u2013364","journal-title":"Nat Chem Biol"},{"key":"11423_CR68","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jmgm.2008.11.008","volume":"27","author":"Q-Q Xie","year":"2009","unstructured":"Xie Q-Q, Xie H-Z, Ren J-X, Li L-L, Yang S-Y (2009) Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J Mol Graph Model 27:751\u2013758","journal-title":"J Mol Graph Model"},{"key":"11423_CR69","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejmech.2018.11.059","volume":"163","author":"M Montana","year":"2019","unstructured":"Montana M, Mathias F, Terme T, Vanelle P (2019) Antitumoral activity of Quinoxaline derivatives: a systematic review. Eur J Med Chem 163:136\u2013147","journal-title":"Eur J Med Chem"},{"key":"11423_CR70","doi-asserted-by":"publisher","first-page":"106735","DOI":"10.1016\/j.bioorg.2023.106735","volume":"139","author":"MMF Ismail","year":"2023","unstructured":"Ismail MMF, Shawer TZ, Ibrahim RS, Allam RM, Ammar YA (2023) Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis. Bioorg Chem 139:106735","journal-title":"Bioorg Chem"},{"key":"11423_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bioorg.2014.05.010","volume":"56","author":"MI Shahin","year":"2014","unstructured":"Shahin MI, Ella DAAE, Ismail NSM, Abouzid KA (2014) M. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on Quinoxaline scaffold. Bioorg Chem 56:16\u201326","journal-title":"Bioorg Chem"},{"key":"11423_CR72","doi-asserted-by":"publisher","first-page":"104807","DOI":"10.1016\/j.bioorg.2021.104807","volume":"110","author":"NA Alsaif","year":"2021","unstructured":"Alsaif NA, Dahab MA, Alanazi MM, Obaidullah AJ, Mehizia MAA, Alanazi MM, Aldawas S, Mahdy HA, Elkady H (2021) New Quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: design, molecular modeling, and synthesis. Bioorg Chem 110:104807","journal-title":"Bioorg Chem"},{"key":"11423_CR73","doi-asserted-by":"publisher","first-page":"30315","DOI":"10.1039\/D1RA05925D","volume":"11","author":"MM Alanazi","year":"2021","unstructured":"Alanazi MM, Elkady HA, Alsaif NA, Obaidullah AJ, Alkahtani HM, Alanazi MM, Alharbi MA, Eissa IH, Dahab MA (2021) RSC Adv 11:30315","journal-title":"RSC Adv"},{"key":"11423_CR74","doi-asserted-by":"crossref","unstructured":"Yousef RG, Sakr HM, Eissa IH, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, El-Adl K (2021) New quinoxaline-2(1H)-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. N J Chem 45(36):16949\u201316964","DOI":"10.1039\/D1NJ02509K"},{"key":"11423_CR75","doi-asserted-by":"publisher","first-page":"105105","DOI":"10.1016\/j.bioorg.2021.105105","volume":"114","author":"K El-Adl","year":"2021","unstructured":"El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, Eissa IH (2021) Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorg Chem 114:105105","journal-title":"Bioorg Chem"},{"key":"11423_CR76","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14756366.2021.1915303","volume":"36","author":"NA Alsaif","year":"2021","unstructured":"Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Al- Alanazi MM, Aldawas S, Elwan A, Elkady H (2021) Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3\u2019,4\u2019-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enz Inhibit Med Chem 36:1093\u20131114","journal-title":"J Enz Inhibit Med Chem"},{"key":"11423_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z, Xiong W (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17:1\u201314","journal-title":"Mol Cancer"},{"key":"11423_CR78","doi-asserted-by":"crossref","unstructured":"Knudsen BS, Woude GV (2008) Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 18(1):87\u201396","DOI":"10.1016\/j.gde.2008.02.001"},{"key":"11423_CR79","doi-asserted-by":"publisher","first-page":"Articlenumber26","DOI":"10.1186\/s12943-018-0795-z","volume":"17","author":"L Demkova","year":"2018","unstructured":"Demkova L, Kucerova L (2018) Role of the HGF\/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol Cancer 17:26","journal-title":"Mol Cancer"},{"key":"11423_CR80","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung P, Pairish M, Jia L, Meng J, Funk L, Botrous I (2011) Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342\u20136363","journal-title":"J Med Chem"},{"key":"11423_CR81","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejmech.2013.04.028","volume":"65","author":"R Ingle","year":"2013","unstructured":"Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. Eur J Med Chem 65:168\u2013186","journal-title":"Eur J Med Chem"},{"key":"11423_CR82","doi-asserted-by":"publisher","first-page":"126666","DOI":"10.1016\/j.bmcl.2019.126666","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang Y, Li Y, Hou Y, Qin M, Gong P, Liu J, Zhao Y (2019) Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor. Bioorg Med Chem Lett 29:126666","journal-title":"Bioorg Med Chem Lett"},{"key":"11423_CR83","doi-asserted-by":"publisher","first-page":"127189","DOI":"10.1016\/j.bmcl.2020.127189","volume":"30","author":"SC Kim","year":"2020","unstructured":"Kim SC, Boggu PR, Yu HN, Ki SY, Jung JM, Kim YS, Park GM, Ma SH, Kim IS, Jung YH (2020) Synthesis and biological evaluation of Quinoxaline derivatives as specific c-Met kinase inhibitors. Bioorg Med Chem Lett 30:127189","journal-title":"Bioorg Med Chem Lett"},{"key":"11423_CR84","doi-asserted-by":"publisher","first-page":"188631","DOI":"10.1016\/j.bbcan.2021.188631","volume":"1876","author":"S Pathania","year":"2021","unstructured":"Pathania S, Pentik\u00e4inen OT, Singh PK (2021) A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochim Biophys Acta - Rev Cancer 1876:188631","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"11423_CR85","doi-asserted-by":"publisher","first-page":"598855","DOI":"10.3389\/fgene.2021.598855","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Shui L, Liu Y, Zheng M (2021) C-Kit, a Double-Edged sword in liver regeneration and diseases. Front Genet 12:598855","journal-title":"Front Genet"},{"key":"11423_CR86","doi-asserted-by":"publisher","unstructured":"Siehl J, Thiel E, Book Targeted therapies in Cancer. C-kit, GIST, and Imatinib 12:145\u2013151, Springer, https:\/\/doi.org\/10.1007\/978-3-540-46091-6_12","DOI":"10.1007\/978-3-540-46091-6_12"},{"key":"11423_CR87","doi-asserted-by":"publisher","first-page":"eaaz2481","DOI":"10.1126\/scitranslmed.aaz2481","volume":"12","author":"E Banks","year":"2020","unstructured":"Banks E, Grondine M, Bhavsar D, Barry E, Kettle JG, Reddy VP, Brown C, Wang H, Mettetal JT, Collins T, Adeyemi O, Overman R, Lawson D, Harmer AR, Reimer C, Drew L, Packer MJ, Cosulich S, Jones RDO, Shao W, Wilson D, Guichard S, Fawell S, Anjum R (2020) Discovery and pharmacological characterization of AZD3229, a potent KIT\/PDGFR\u03b1 inhibitor for treatment of gastrointestinal stromal tumors. Sci Transl Med 12:eaaz2481","journal-title":"Sci Transl Med"},{"key":"11423_CR88","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejmech.2014.08.048","volume":"86","author":"SA Galal","year":"2014","unstructured":"Galal SA, Khairat SHM, Ragab FAF, Abdelsamie AS, Ali MM, Soliman SM, Mortier J, Wolber G, Diwani H (2014) I.E. Design, synthesis and molecular Docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with Inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity. Eur J Med Chem 86:122\u2013132","journal-title":"Eur J Med Chem"},{"key":"11423_CR89","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.saa.2017.12.063","volume":"195","author":"Z Ghanbarimasir","year":"2018","unstructured":"Ghanbarimasir Z, Bekhradnia A, Morteza-Semnani K, Rafiei A, Razzaghi-Asl N, Kardan M (2018) Design, synthesis, biological assessment and molecular docking studies of new 2-aminoimidazole-quinoxaline hybrids as potential anticancer agents. Spectrochim Acta A Mol Biomol Spectrosc SPECTROCHIM ACTA A 195:21\u201335","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc SPECTROCHIM ACTA A"},{"key":"11423_CR90","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers 9:52","journal-title":"Cancers"},{"key":"11423_CR91","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","volume":"17","author":"F Chang","year":"2003","unstructured":"Chang F, Steelman L, Lee J et al (2003) Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263\u20131293","journal-title":"Leukemia"},{"key":"11423_CR92","doi-asserted-by":"publisher","first-page":"130317","DOI":"10.1016\/j.molstruc.2021.130317","volume":"1236","author":"EA Fayed","year":"2021","unstructured":"Fayed EA, Ammar YA, Saleh MA, Bayoumi AH, Belal A, Mehany ABM, Ragab A, Design (2021) synthesis, antiproliferative evaluation, and molecular Docking study of new Quinoxaline derivatives as apoptotic inducers and EGFR inhibitors. J Mol Struct 1236:130317","journal-title":"J Mol Struct"},{"issue":"32","key":"11423_CR93","doi-asserted-by":"publisher","first-page":"24814","DOI":"10.1039\/C5RA02576A","volume":"5","author":"X Zong","year":"2015","unstructured":"Zong X et al (2015) Discovery of 3, 3 a, 4, 5-tetrahydro-2 H-benzo [g] Indazole containing Quinoxaline derivatives as novel EGFR\/HER-2 dual inhibitors. RSC Adv 5(32):24814\u201324823","journal-title":"RSC Adv"},{"issue":"5","key":"11423_CR94","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/molecules26051490","volume":"26","author":"M Kumar","year":"2021","unstructured":"Kumar M et al (2021) Design and synthesis of non-covalent Imidazo [1, 2-a] quinoxaline-based inhibitors of EGFR and their anti-cancer assessment. Molecules 26(5):1490","journal-title":"Molecules"},{"issue":"3","key":"11423_CR95","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1134\/S1068162022030220","volume":"48","author":"V Badithapuram","year":"2022","unstructured":"Badithapuram V et al (2022) Design, synthesis, and molecular Docking studies of some new Quinoxaline derivatives as EGFR targeting agents. Russ J Bioorg Chem 48(3):565\u2013575","journal-title":"Russ J Bioorg Chem"},{"issue":"18","key":"11423_CR96","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1039\/D3RA01635H","volume":"13","author":"MA Ismail","year":"2023","unstructured":"Ismail MA et al (2023) A new class of anti-proliferative activity and apoptotic inducer with molecular Docking studies for a novel of 1, 3-dithiolo [4, 5-b] Quinoxaline derivatives hybrid with a sulfonamide moiety. RSC Adv 13(18):12589\u201312608","journal-title":"RSC Adv"},{"issue":"1","key":"11423_CR97","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/molecules23010048","volume":"23","author":"M Alswah","year":"2017","unstructured":"Alswah M et al (2017) Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing Triazolo [4, 3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects. Molecules 23(1):48","journal-title":"Molecules"},{"issue":"12","key":"11423_CR98","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1002\/jhet.4144","volume":"57","author":"HS El Saeed","year":"2020","unstructured":"El Saeed HS et al (2020) Synthesis of novel triazoloquinoxaline-pyrazole hybrids as antiproliferatives, EGFR inhibitors, and apoptosis inducers. J Heterocycl Chem 57(12):4358\u20134372","journal-title":"J Heterocycl Chem"},{"issue":"19","key":"11423_CR99","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1080\/00397911.2020.1787448","volume":"50","author":"EA Ahmed","year":"2020","unstructured":"Ahmed EA et al (2020) Synthesis, EGFR-TK Inhibition and anticancer activity of new quinoxaline derivatives. Synth Commun 50(19):2924\u20132940","journal-title":"Synth Commun"},{"key":"11423_CR100","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cytogfr.2004.09.002","volume":"15","author":"H Surawska","year":"2004","unstructured":"Surawska H, Ma PC, Salgia R (2004) The role of Ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419\u2013433","journal-title":"Cytokine Growth Factor Rev"},{"key":"11423_CR101","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ceb.2010.08.005","volume":"22","author":"M Genander","year":"2010","unstructured":"Genander M, Frise\u00b4 n J (2010) Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol 22:611\u2013616","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"11423_CR102","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1021\/ml3001984","volume":"3","author":"H Zhao","year":"2012","unstructured":"Zhao H, Dong J, Lafleur K, Nevado C, Caflisch A (2012) Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics. ACS Med Chem Lett 3(10):834\u2013838","journal-title":"ACS Med Chem Lett"},{"key":"11423_CR103","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.1021\/jm5009242","volume":"57","author":"A Unzue","year":"2014","unstructured":"Unzue A, Dong J, Lafleur K, Zhao H, Frugier E, Caflisch A, Nevado C (2014) Pyrrolo [3,2-b] Quinoxaline derivatives as types i1\/2 and Ii Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation. J Med Chem 57:15:6834\u20136844","journal-title":"J Med Chem"},{"key":"11423_CR104","doi-asserted-by":"publisher","first-page":"e19923","DOI":"10.1371\/journal.pone.0019923","volume":"6","author":"H Zhao","year":"2011","unstructured":"Zhao H, Huang D (2011) Hydrogen bonding penalty upon ligand binding. PLoS ONE 6:e19923","journal-title":"PLoS ONE"},{"issue":"116","key":"11423_CR105","doi-asserted-by":"publisher","first-page":"pp665","DOI":"10.1039\/D0MD00049C","volume":"2020","author":"A Unzue","year":"2020","unstructured":"Unzue A, Jessen-Trefzer C, Spiliotopoulos D, Gaudio E, Tarantelli C, Dong J, Zhao H, Pachmayr J, Zahler S, Bernasconi E, Sartori G (2020) Understanding the mechanism of action of Pyrrolo [3, 2-b] quinoxaline-derivatives as kinase inhibitors. RSC Med Chem 2020(116):665\u2013675","journal-title":"RSC Med Chem"},{"key":"11423_CR106","doi-asserted-by":"publisher","first-page":"p103055","DOI":"10.1016\/j.bioorg.2019.103055","volume":"90","author":"Z Rezaei","year":"2019","unstructured":"Rezaei Z, Didehvar MM, Mahdavi M, Azizian H, Hamedifar H, Mohammed EH, Ostad S, Amini M (2019) Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors. Bioorg Chem 90:103055","journal-title":"Bioorg Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11423-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11423-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:02:39Z","timestamp":1783162959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11423-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":106,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["11423"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11423-z","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}